Article: Tamsulosin

Tamsulosin
Systematic (IUPAC) name
(R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)- 2-methoxybenzenesulfonamide
Identifiers
CAS number	106133-20-4
ATC code	G04CA02
PubChem	129211
DrugBank	APRD00036
Chemical data
Formula	C20H28N2O5S
Mol. weight	408.51
Pharmacokinetic data
Bioavailability	100% (oral)
Metabolism	hepatic
Half life	9–13 hours
Excretion	76% renal
Therapeutic considerations
Pregnancy cat.	B2 (Aust)
Legal status	Schedule 4 (Aust) POM (UK)
Routes	oral

Tamsulosin (rINN) (IPA: [tæmˈsulosɪn, tæmsuˈlosɪn, ]) is an α_1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin was developed by Yamanouchi Pharmaceuticals (now part of Astellas Pharma) and is marketed by various companies under licence, including Boehringer-Ingelheim and CSL. As of 2006, tamsulosin hydrochloride extended-release tablets are marketed under the trade name Flomaxtra. It was formerly marketed as modified-release capsules under the trade name Flomax.

Clinical use

Main article: Alpha blocker